Gemcitabine

製品コードS1714 別名：LY-188011, NSC 613327

Gemcitabine 化学構造

分子量(MW)：263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

サイズ 価格(税別)  
JPY 21580.00
JPY 16102.00
お問い合わせ バルク問合せ

文献中Selleckの製品使用例(21)

カスタマーフィードバック(5)

  • RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

    Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

  • a: KMBC (blue circles) and HuCCT1 (purple squares) cells were plated in 384-well plates (1,000 cells/well), and incubated with varying concentrations of gemcitabine. Cell viability was assessed after 72 h using Cell Titer GloR 2.0 assay. Data represents the average percent cell viability plotted against concentration of drug in nM from 4 replicates for each condition.

    Mol Cancer, 2017, 16(1):22. Gemcitabine purchased from Selleck.

    Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明 Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMECwOFU5KG6P NV7CWJRqW0GQR1XS
ES4 M1TFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHnTWM2OD1yLkCwNFY2OyCwTR?= NYPIcIEzW0GQR1XS
ACHN MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi5T5hIUUN3ME2wMlAxODh6NzDuUS=> Mn36V2FPT0WU
KYSE-510 NYDueGpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;hV3NsUUN3ME2wMlAxODl5NTDuUS=> MlKxV2FPT0WU
EW-7 M2i5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jkdGlEPTB;MD6wNFI2QCCwTR?= NF;DcoxUSU6JRWK=
BFTC-905 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDibVJ2UUN3ME2wMlAxPTF3IH7N M{\BWHNCVkeHUh?=
KE-37 NVGyZYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HPeWlEPTB;MD6wNFU3OSCwTR?= MXXTRW5ITVJ?
SBC-5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXKe3RKSzVyPUCuNFA2PyCwTR?= MUTTRW5ITVJ?
NKM-1 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TvVGlEPTB;MD6wNFcxQSCwTR?= NIH5[GhUSU6JRWK=
RH-1 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEC3NVghdk1? MmjvV2FPT0WU
ALL-PO NFnpdodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorBTWM2OD1yLkCwPFMhdk1? MmrYV2FPT0WU
QIMR-WIL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHHfWI{UUN3ME2wMlAxQDl2IH7N M2PSenNCVkeHUh?=
A375 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDmRnNKSzVyPUCuNFA6QTVibl2= MlvlV2FPT0WU
SIG-M5 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEGwOEBvVQ>? MYnTRW5ITVJ?
KGN NFf4WZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvvTWM2OD1yLkCxNFghdk1? NUTEeGt2W0GQR1XS
EW-13 NVLzZ2lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzXd3JKSzVyPUCuNFEyOiCwTR?= NILiSJlUSU6JRWK=
NCI-SNU-1 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3VZdKSzVyPUCuNFE3KG6P MVfTRW5ITVJ?
PSN1 M{nzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPZWodKSzVyPUCuNFE3PSCwTR?= Mom2V2FPT0WU
HUTU-80 NEe1e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTMTWM2OD1yLkCxOlYhdk1? MoTTV2FPT0WU
EW-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fBNWlEPTB;MD6wNlMhdk1? MWjTRW5ITVJ?
786-0 NXrITG1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEKzJI5O M4riXnNCVkeHUh?=
ES1 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq0bI1KSzVyPUCuNFI3QCCwTR?= NEnkXpFUSU6JRWK=
RKO NHXySmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\aTHBKSzVyPUCuNFI4QSCwTR?= MojtV2FPT0WU
ESS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEK4OkBvVQ>? NXLUfVVIW0GQR1XS
SK-UT-1 NYO5PFRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH72Zo1KSzVyPUCuNFI6PyCwTR?= Mor3V2FPT0WU
LB2241-RCC NFPuZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG1TWM2OD1yLkCzNVghdk1? M1LaTXNCVkeHUh?=
CHL-1 M1;sXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[3NlBKSzVyPUCuNFMzPCCwTR?= MnrXV2FPT0WU
SW1783 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj2c45KSzVyPUCuNFM{PiCwTR?= NYqzN5p3W0GQR1XS
MEL-JUSO MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHSTWM2OD1yLkCzPVEhdk1? M3PKRnNCVkeHUh?=
HT-29 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTZTWM2OD1yLkC0NVMhdk1? M3PmN3NCVkeHUh?=
SNG-M NHTwbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLaSXpsUUN3ME2wMlA1OjVibl2= MojWV2FPT0WU
TE-15 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32xXGlEPTB;MD6wOFY1KG6P NFnvWY1USU6JRWK=
HOS M1LjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnoXHVVUUN3ME2wMlA1QCCwTR?= MYHTRW5ITVJ?
BB65-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LmVWlEPTB;MD6wOVEzKG6P M3rJb3NCVkeHUh?=
HCE-4 NEToSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEWyPEBvVQ>? NHzZdJlUSU6JRWK=
MHH-ES-1 NVv2OIdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfETWM2OD1yLkC1N|Ehdk1? MV;TRW5ITVJ?
RPMI-7951 M2PRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TyUmlEPTB;MD6wOVQyKG6P NH;IfJVUSU6JRWK=
IST-SL2 M1rrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPKXItKSzVyPUCuNFU5PCCwTR?= NGrlNVBUSU6JRWK=
CMK NFTC[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n3XmlEPTB;MD6wOVg3KG6P NFTPWGhUSU6JRWK=
GR-ST NHjnfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHVTWM2OD1yLkC1PVUhdk1? NYjVSWFVW0GQR1XS
NALM-6 NIrKXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrkNVM5UUN3ME2wMlA3OjJibl2= NI\rNnBUSU6JRWK=
RPMI-6666 NGfGPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M335dWlEPTB;MD6wOlUzKG6P Ml3hV2FPT0WU
LC-2-ad MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M136cmlEPTB;MD6wOlU{KG6P Mn\vV2FPT0WU
ARH-77 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnPTWM2OD1yLkC3NVEhdk1? NU\GVFM2W0GQR1XS
IST-MEL1 NIfXWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\rOWlEPTB;MD6wO|I3KG6P MoLoV2FPT0WU
SW1710 M3v1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonzTWM2OD1yLkC3OVEhdk1? NV\vXFhOW0GQR1XS
DEL MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLJVnZLUUN3ME2wMlA5QDdibl2= M3Hx[XNCVkeHUh?=
AGS NGfOSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LsfGlEPTB;MD6wPVAzKG6P NYHqeHJTW0GQR1XS
NCI-H2122 NXL6XJUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn6XZRKSzVyPUCuNFk1PiCwTR?= NXX5V|NnW0GQR1XS
HSC-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUCyJI5O NWn1NlVMW0GQR1XS
AM-38 NXfzT2J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4juU2lEPTB;MD6xNlEhdk1? MWLTRW5ITVJ?
769-P MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\vTWM2OD1yLkGyN{BvVQ>? Mly2V2FPT0WU
RT-112 M4[2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\uTWM2OD1yLkGyO{BvVQ>? MUnTRW5ITVJ?
MCF7 M2\5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\hTWM2OD1yLkGzOkBvVQ>? NVz3bXl1W0GQR1XS
IGROV-1 M2jNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMUS1JI5O NED4VZdUSU6JRWK=
OCI-AML2 NICyZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\3SWlEPTB;MD6xOFchdk1? NFftfpRUSU6JRWK=
NCI-H1299 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnTeJo{UUN3ME2wMlE2PyCwTR?= MYXTRW5ITVJ?
A431 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUizJI5O NFLtToVUSU6JRWK=
SW982 NWezUWx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{foVGlEPTB;MD6yNVMhdk1? NGf3[YNUSU6JRWK=
BB30-HNC MlH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTkTpVKSzVyPUCuNlMyKG6P Mn;hV2FPT0WU
ACN NW\pXZcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTpTWM2OD1yLkK0OEBvVQ>? Mn3CV2FPT0WU
647-V M1uyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPpVFBKSzVyPUCuNlQ5KG6P NFmyTW5USU6JRWK=
SK-PN-DW NFX3UnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzzZ2JUUUN3ME2wMlI3PiCwTR?= MXPTRW5ITVJ?
LCLC-97TM1 M4jGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP1OZJKSzVyPUCuNlY4KG6P NUTpUJBsW0GQR1XS
LB1047-RCC NXrGOXRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMk[5JI5O MnTyV2FPT0WU
A2780 NHPv[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TRdGlEPTB;MD6yO{BvVQ>? M3XsTHNCVkeHUh?=
C-33-A NUHpRpEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXNUIQ5UUN3ME2wMlI4OyCwTR?= M2LZTHNCVkeHUh?=
NCI-H2228 NGLpeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXiTWM2OD1yLkOxOEBvVQ>? MWHTRW5ITVJ?
TE-5 NEXTZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLxTWM2OD1yLkOxOkBvVQ>? NGW0VJRUSU6JRWK=
HC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rOdmlEPTB;MD6zNlchdk1? M3q1TnNCVkeHUh?=
SK-MES-1 NU\tVI5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPTNGRKSzVyPUCuN|I5KG6P MWDTRW5ITVJ?
NCI-H1355 NEDxZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu1UGpKSzVyPUCuN|gyKG6P MmHDV2FPT0WU
YKG-1 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rEbGlEPTB;MD60NVkhdk1? NV3h[m1qW0GQR1XS
RS4-11 NYDPelc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNEOzJI5O MkLFV2FPT0WU
Daoy M{Xvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDXSHl7UUN3ME2wMlQ2PiCwTR?= M3PKe3NCVkeHUh?=
A3-KAW NFXEZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNUWxJI5O NHTXXo9USU6JRWK=
SK-MEL-30 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjTTWM2OD1yLkW1OEBvVQ>? NF\sOGlUSU6JRWK=
U031 NEPRZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\JcmlEPTB;MD61OlUhdk1? NGT3fJJUSU6JRWK=
SK-LMS-1 NHX2VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW4WWFKSzVyPUCuOVc5KG6P NVjUd|dxW0GQR1XS
ES6 NFz0SoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lt[2lEPTB;MD61PFYhdk1? NHjrdpFUSU6JRWK=
EoL-1-cell MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNkG2JI5O M3fUV3NCVkeHUh?=
NCI-H2009 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjPXWEyUUN3ME2wMlYyQSCwTR?= M33y[3NCVkeHUh?=
A4-Fuk MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLRSGg5UUN3ME2wMlYzPiCwTR?= MXjTRW5ITVJ?
KYSE-270 M1PrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNkO0JI5O MUDTRW5ITVJ?
SK-LU-1 NFn1UFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNkW1JI5O MmDmV2FPT0WU
SW872 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDETWM2OD1yLke2OUBvVQ>? NHH3NGZUSU6JRWK=
ES8 NFHkOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MneyTWM2OD1yLke4JI5O NWn4cXplW0GQR1XS
G-402 MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwN{i0JI5O NF3EZ4dUSU6JRWK=
ATN-1 Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPMTWM2OD1yLkiwO{BvVQ>? M{XlcnNCVkeHUh?=
DoTc2-4510 MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\0fXVXUUN3ME2wMlkxOSCwTR?= MV\TRW5ITVJ?
MES-SA M1vTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPHTWM2OD1yLkmwOUBvVQ>? MkT0V2FPT0WU
SF268 M3K2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTzUpQ3UUN3ME2wMlkzPyCwTR?= MVjTRW5ITVJ?
SF539 M2Dm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn1N4pDUUN3ME2xMlAzKG6P Mly0V2FPT0WU
NB69 NXK4dGdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfRe2RVUUN3ME2xMlA2KG6P MmHJV2FPT0WU
8505C NEOxbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPJTWM2OD1zLkC2JI5O MmrkV2FPT0WU
CAL-12T M2\yPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTCTWM2OD1zLkC4JI5O Mn3WV2FPT0WU
BHY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwMUSgcm0> NH7m[m5USU6JRWK=
LB647-SCLC NYC3S3Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK4dYdGUUN3ME2xMlE5KG6P NVjVUo1oW0GQR1XS
CAL-62 NGO1[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXIUo9RUUN3ME2xMlIzKG6P MUDTRW5ITVJ?
MEG-01 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwMkegcm0> MljrV2FPT0WU
MG-63 NWf0UoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpTWM2OD1zLkOzJI5O NGfZbHJUSU6JRWK=
SW620 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;qTnA4UUN3ME2xMlM2KG6P MkW1V2FPT0WU
A388 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDDb4dKSzVyPUGuN|Yhdk1? NEXDOVlUSU6JRWK=
BCPAP NUP4R|RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nKdmlEPTB;MT60OUBvVQ>? NH\TZ21USU6JRWK=
P30-OHK NEC3[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;kdVFJUUN3ME2xMlQ3KG6P M2T3eXNCVkeHUh?=
Ca9-22 NVzzZ283T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XLSGlEPTB;MT61OEBvVQ>? Mnu1V2FPT0WU
VMRC-RCZ MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLXTWM2OD1zLkW0JI5O MnK4V2FPT0WU
LOXIMVI Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CycWlEPTB;MT62JI5O NH:5OmhUSU6JRWK=
L-540 NIfUXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L4emlEPTB;MT62JI5O M2jwV3NCVkeHUh?=
NTERA-S-cl-D1 NF7DUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zWSWlEPTB;MT62OEBvVQ>? MmLBV2FPT0WU
MFH-ino NWTMTVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrWTWM2OD1zLk[2JI5O M4LvTHNCVkeHUh?=
Calu-6 NHnoS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fzXWlEPTB;MT63N{BvVQ>? NVjOXWEyW0GQR1XS
HEL NHjKTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTGTWM2OD1zLke5JI5O MVzTRW5ITVJ?
CAL-33 NH;ZNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHizNG9KSzVyPUGuPFkhdk1? MnnVV2FPT0WU
HSC-3 NF33V2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFwOUGgcm0> M1;MV3NCVkeHUh?=
KU812 NF7WcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrvdm5KSzVyPUGuPVEhdk1? M2rXUHNCVkeHUh?=
EB2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJwMEGgcm0> NHLucXdUSU6JRWK=
SR MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzldGVIUUN3ME2yMlEzKG6P M1HSWXNCVkeHUh?=
NCI-H2087 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJwMUSgcm0> NUnObFZzW0GQR1XS
H4 NUXMe41jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJwMUigcm0> MX;TRW5ITVJ?
EW-1 M1zKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G0dmlEPTB;Mj6yNkBvVQ>? M1\nVHNCVkeHUh?=
MC-IXC NUXBTYVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwMk[gcm0> NVTMUGRSW0GQR1XS
NCI-H727 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInzOmdKSzVyPUKuOVEhdk1? MWXTRW5ITVJ?
MRK-nu-1 NI\oNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwNUegcm0> MlK1V2FPT0WU
COLO-668 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m1eGlEPTB;Mj62OkBvVQ>? MULTRW5ITVJ?
CGTH-W-1 NYTzPZJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTNS5lKSzVyPUKuO|Ihdk1? M13CUnNCVkeHUh?=
CHP-212 NFm3XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJwN{Wgcm0> NFH5cpBUSU6JRWK=
GI-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJwN{[gcm0> NWjiWZd1W0GQR1XS
HCC1806 NVv1OY9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\4TWM2OD1{LkmxJI5O MljoV2FPT0WU
HLE M3Lldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNibl2= NX3ONYI2W0GQR1XS
HSC-2 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILaOmFKSzVyPUOuNFMhdk1? Mn3lV2FPT0WU
DMS-273 M{TIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj2TWM2OD1|LkC3JI5O NFvLU|dUSU6JRWK=
DU-4475 Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrYTWM2OD1|LkG0JI5O NFewZmFUSU6JRWK=
LXF-289 NUW0TphyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTSSmNNUUN3ME2zMlMyKG6P MnftV2FPT0WU
PANC-03-27 NU[0VZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHKbJJKSzVyPUOuOVEhdk1? NFrhWG5USU6JRWK=
GAMG NFLBTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjkS4xlUUN3ME2zMlc1KG6P MonnV2FPT0WU
NCI-H522 M1n0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrEN5NLUUN3ME20MlM1KG6P MUXTRW5ITVJ?
SW626 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\mclhWUUN3ME20MlQ3KG6P MVzTRW5ITVJ?
HT-144 NVHY[4RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LWSWlEPTB;ND65NkBvVQ>? NXXYT2dEW0GQR1XS
MEL-HO M{[3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjFc4JZUUN3ME21MlE3KG6P M2HrWnNCVkeHUh?=
BE-13 NWXQZ29qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXCbHVqUUN3ME21MlIyKG6P NHLIc5JUSU6JRWK=
VA-ES-BJ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC0TWM2OD13LkK2JI5O NYC3dHVSW0GQR1XS
NCI-H441 NHP1U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD13Lk[gcm0> NHHhSFVUSU6JRWK=
KP-4 M2XCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfrWZVKSzVyPUWuOlEhdk1? NWPTWYR6W0GQR1XS
LoVo NF3MbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rNTWlEPTB;NT63NUBvVQ>? M3\QNXNCVkeHUh?=
HT-1080 NHXrO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTVwOEOgcm0> MUPTRW5ITVJ?
GB-1 NX7ZcY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13TVGlEPTB;NT64OEBvVQ>? MUfTRW5ITVJ?
IA-LM NGTYdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTZS25KSzVyPUWuPVEhdk1? MlfMV2FPT0WU
8-MG-BA NXjHTHM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;6WphVUUN3ME21Mlk{KG6P M1fUWXNCVkeHUh?=
SK-HEP-1 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK0ephKSzVyPU[uNVQhdk1? NXLvVmFTW0GQR1XS
697 NXe0d3Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvTpVKSzVyPU[uNlUhdk1? NW\EUFlTW0GQR1XS
KYSE-450 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\4[IhvUUN3ME22MlMzKG6P M4Hhb3NCVkeHUh?=
HCC2998 M3T3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Xmc2lEPTB;Nj6zOEBvVQ>? MnqzV2FPT0WU
HD-MY-Z Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDnUoFIUUN3ME22MlY5KG6P MlW1V2FPT0WU
OS-RC-2 NF61eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[1RmlEPTB;Nj62PEBvVQ>? NYDafZJ1W0GQR1XS
SF126 NWD4cWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITCT4ZKSzVyPUeuNFUhdk1? MVTTRW5ITVJ?
Ca-Ski MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLOZWNKSzVyPUeuNFkhdk1? M3n0NHNCVkeHUh?=
NCI-H358 NF3hXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfTTWM2OD15LkG2JI5O Mn;XV2FPT0WU
J82 NHXIbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j2NGlEPTB;Nz60NUBvVQ>? M1rqU3NCVkeHUh?=
NCI-H2342 NES5XYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljvTWM2OD15Lk[zJI5O NIfDXlFUSU6JRWK=
OVCAR-8 MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuySohKSzVyPUeuPUBvVQ>? M3;z[3NCVkeHUh?=
TE-8 M{LSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\lTWM2OD16IH7N MWnTRW5ITVJ?
ETK-1 NGDFVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPkTWM2OD16LkC4JI5O NEHMWXBUSU6JRWK=
HAL-01 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzXeGJLUUN3ME24MlIhdk1? MYXTRW5ITVJ?
KYSE-150 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRThwNEegcm0> Mme1V2FPT0WU
NCI-H810 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRThwNU[gcm0> M4DJc3NCVkeHUh?=
ONS-76 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwNkigcm0> NWixZnM5W0GQR1XS
NMC-G1 NUjpeodvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvzbFdKSzVyPUiuO|Yhdk1? M4K4Z3NCVkeHUh?=
C3A MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHRcmJSUUN3ME24Mlg1KG6P MkXSV2FPT0WU
PA-1 NUPqNHhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki1TWM2OD16Lkm5JI5O MkmxV2FPT0WU
SH-4 NF3IW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH6VHZKSzVyPUmuNFIhdk1? NYPWXoZ3W0GQR1XS
EFO-27 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTlwMEWgcm0> NImxb3BUSU6JRWK=
CAPAN-1 NEPPfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfzTWM2OD17LkKzJI5O NI\WTVZUSU6JRWK=
DU-145 M{XOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnSW4JKSzVyPUmuNlkhdk1? M2TO[3NCVkeHUh?=
A101D MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTlwM{egcm0> M3\CUHNCVkeHUh?=
ST486 M3TDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTlwNEGgcm0> MlfMV2FPT0WU
NCI-H1437 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PIdGlEPTB;OT60NkBvVQ>? MX\TRW5ITVJ?
HGC-27 NX63XVBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTEN2dKSzVyPUmuOkBvVQ>? M3:2XHNCVkeHUh?=
8305C MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTlwNkSgcm0> NHPzV|lUSU6JRWK=
OCUB-M M3fsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFyLkCzJI5O MXvTRW5ITVJ?
COLO-679 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;EdmlEPTB;MUCuNFchdk1? NWDtdY9xW0GQR1XS
Detroit562 M1nVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFyLkSyJI5O MmfWV2FPT0WU
A204 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDpN2YzUUN3ME2xNU4yPiCwTR?= MXHTRW5ITVJ?
NCI-H1734 NFTROnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonWTWM2OD1zMT6yPUBvVQ>? M4HMbnNCVkeHUh?=
MC-CAR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jSdmlEPTB;MUGuOVghdk1? MVXTRW5ITVJ?
NCI-H2170 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvYTWM2OD1zMT65O{BvVQ>? MXPTRW5ITVJ?
NCI-SNU-5 NIHaTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\sPIVKSzVyPUGyMlE{KG6P MXrTRW5ITVJ?
HCE-T M2e3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HJUGlEPTB;MUKuOFIhdk1? NVvkSGU6W0GQR1XS
KYSE-180 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXhTWM2OD1zMj64NUBvVQ>? NEnMfnpUSU6JRWK=
C8166 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLmTWM2OD1zMz6wPEBvVQ>? MXPTRW5ITVJ?
NCI-H460 M1nVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfqdHJsUUN3ME2xN{42PCCwTR?= NF2zV2tUSU6JRWK=
SNU-449 NGjROGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M174NGlEPTB;MUOuO|chdk1? NVThdINKW0GQR1XS
MDA-MB-468 NVPL[GxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnJSIZKSzVyPUG0MlEzKG6P NIf1T3RUSU6JRWK=
COR-L23 M1G0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF2LkGzJI5O NXnrfmpVW0GQR1XS
CTV-1 M2XRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF2LkG0JI5O M13jenNCVkeHUh?=
BL-41 NVzLelgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF2LkO3JI5O NH:zW5RUSU6JRWK=
IGR-1 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj5enltUUN3ME2xOE41OiCwTR?= MVrTRW5ITVJ?
TK10 NITqbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[w[HM5UUN3ME2xOE41QSCwTR?= NGfXcWNUSU6JRWK=
REH M16ybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\CTGlEPTB;MUSuOVEhdk1? M1;5ZnNCVkeHUh?=
LU-139 NHjHZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF2LkW5JI5O NHXvW|BUSU6JRWK=
KP-N-YS NGDPXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\JN|FGUUN3ME2xOE46PyCwTR?= NEHFeHdUSU6JRWK=
PANC-10-05 M4L3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O0ZWlEPTB;MUWuN|ghdk1? NVH5R2pHW0GQR1XS
HL-60 NGD2U25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXXTGVKSzVyPUG1MlY6KG6P MkHMV2FPT0WU
T84 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorlTWM2OD1zNT65OkBvVQ>? MUXTRW5ITVJ?
RPMI-8226 NWCweXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF4LkCyJI5O NE\LRoVUSU6JRWK=
UM-UC-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF4LkG2JI5O NFW4SJdUSU6JRWK=
TE-10 M3rGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3GTWM2OD1zNj6yNUBvVQ>? NI\0dm5USU6JRWK=
CAL-148 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTaOZJbUUN3ME2xO{4zOyCwTR?= MX7TRW5ITVJ?
BV-173 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\hcHJTUUN3ME2xO{4zPyCwTR?= M1faUHNCVkeHUh?=
Calu-3 NUe0N4FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfGTINwUUN3ME2xO{4zQSCwTR?= M1\hOXNCVkeHUh?=
RPMI-2650 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PyXGlEPTB;MUeuOVkhdk1? NGjVbIpUSU6JRWK=
MKN45 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrOcnFkUUN3ME2xO{44OyCwTR?= MX7TRW5ITVJ?
NUGC-3 M1PQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF6LkO0JI5O M37rdnNCVkeHUh?=
NCI-H520 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF6Lke3JI5O NHzMUppUSU6JRWK=
CCRF-CEM Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvwTWM2OD1zOD64OUBvVQ>? MXHTRW5ITVJ?
NCI-H2405 NXXuco4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojETWM2OD1zOT6xJI5O M1vibnNCVkeHUh?=
ES7 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mweWlEPTB;MUmuO|Yhdk1? MV\TRW5ITVJ?
BPH-1 M3XQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj2NmxKSzVyPUKwMlI5KG6P MWnTRW5ITVJ?
SAS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHtTWM2OD1{MD61JI5O M2frR3NCVkeHUh?=
HuCCT1 M3f2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3tTWM2OD1{MD61PEBvVQ>? MlW2V2FPT0WU
LOUCY M2D5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGToUllKSzVyPUKwMlY3KG6P M4rXdXNCVkeHUh?=
NCI-H292 NXG1WHRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJyLke5JI5O M4LGbHNCVkeHUh?=
G-361 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfNTWM2OD1{MT6wO{BvVQ>? M130PHNCVkeHUh?=
M059J NGradodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP1TWM2OD1{MT6wPEBvVQ>? MmrBV2FPT0WU
NCI-H1651 M3jKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGyU45JUUN3ME2yNU4yOSCwTR?= NIP2SJJUSU6JRWK=
KALS-1 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TlbGlEPTB;MkGuN|khdk1? MX3TRW5ITVJ?
DJM-1 NHnNZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW1TWM2OD1{MT61PUBvVQ>? M3nHS3NCVkeHUh?=
AU565 NFzHOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\ZfGlEPTB;MkGuPFMhdk1? NX;lXJhLW0GQR1XS
HCC38 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJzLkm1JI5O MX3TRW5ITVJ?
U251 M3f3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX2XXFKSzVyPUKyMlI4KG6P MU\TRW5ITVJ?
ABC-1 NWDuUJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHsN4Z3UUN3ME2yNk43PSCwTR?= M1zuVXNCVkeHUh?=
SK-NEP-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTsWJZ3UUN3ME2yNk46OyCwTR?= NEK5dZJUSU6JRWK=
CESS Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHyTWM2OD1{Mz6xPUBvVQ>? NYHtSlZFW0GQR1XS
MIA-PaCa-2 NWr2OWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPrNWZKSzVyPUKzMlM3KG6P NEHMbIFUSU6JRWK=
SUP-T1 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHiTWM2OD1{Mz60O{BvVQ>? NYfPdXk2W0GQR1XS
L-428 NFzUSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X2N2lEPTB;MkOuOlIhdk1? MYXTRW5ITVJ?
SW954 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\FVWFKSzVyPUKzMlY5KG6P MXTTRW5ITVJ?
HO-1-N-1 M1rPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PhOmlEPTB;MkOuO|chdk1? NHnFSmxUSU6JRWK=
CHP-126 M2r6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLHTWM2OD1{ND6xOEBvVQ>? M33TZnNCVkeHUh?=
HMV-II MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSwTWM2OD1{ND6zOEBvVQ>? NFTOVppUSU6JRWK=
NB10 NGf0TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jle2lEPTB;MkSuN|chdk1? M4LzVnNCVkeHUh?=
A172 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ2LkexJI5O MYXTRW5ITVJ?
MONO-MAC-6 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGToS4dKSzVyPUK0Mlg1KG6P NVvMXXQ{W0GQR1XS
NCI-H1650 MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJ3LkSgcm0> NEPVRY1USU6JRWK=
NH-12 M2\QWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTpN2ZsUUN3ME2yOU42KG6P MoTYV2FPT0WU
ML-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;CTWM2OD1{NT63OEBvVQ>? MUjTRW5ITVJ?
MZ2-MEL M3vRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ4LkKyJI5O MYnTRW5ITVJ?
COLO-684 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPvTIFKSzVyPUK2MlQyKG6P M2f6enNCVkeHUh?=
HuP-T4 M4S5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i3SGlEPTB;MkeuN{BvVQ>? NW\SVZBtW0GQR1XS
SW837 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ5Lk[yJI5O NGHhSHdUSU6JRWK=
MDA-MB-231 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJ5Lke4JI5O M{jXcXNCVkeHUh?=
KYSE-140 NWHvXoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ5LkmxJI5O NIXqcpZUSU6JRWK=
NOMO-1 NXO0dm8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm2bmFiUUN3ME2yPE43QCCwTR?= NYP2bnZrW0GQR1XS
GP5d MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ6LkeyJI5O M3zQbHNCVkeHUh?=
COR-L105 NEP4V3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD5TWM2OD1{OT60NkBvVQ>? NWP3W5ZjW0GQR1XS
LS-411N M1PQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[4OGlEPTB;MkmuPFghdk1? NEHIbGtUSU6JRWK=
NY NFvUco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNyLkG4JI5O M4nQ[3NCVkeHUh?=
NCI-H2030 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rYVWlEPTB;M{CuOFUhdk1? NWjKXodLW0GQR1XS
CCF-STTG1 NGXPWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n1VWlEPTB;M{GuOFIhdk1? NFjidHdUSU6JRWK=
NCI-H1703 NWL5[3JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33EUmlEPTB;M{GuO|ghdk1? MoPwV2FPT0WU
TUR NYXWRYRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\tfpdrUUN3ME2zNk4xOyCwTR?= NX7RRmdGW0GQR1XS
NOS-1 NYf0O41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPnd49KSzVyPUOyMlQ1KG6P M3vPe3NCVkeHUh?=
A2058 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nUWmlEPTB;M{KuPFMhdk1? MmTMV2FPT0WU
LCLC-103H NFyxepVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzz[WN{UUN3ME2zN{4zPSCwTR?= M4XKRnNCVkeHUh?=
NCI-H510A M{fD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN|LkK3JI5O Mne5V2FPT0WU
BC-1 M1\2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TsfWlEPTB;M{OuO|chdk1? MljyV2FPT0WU
SK-CO-1 M1zHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H3XmlEPTB;M{SuNFEhdk1? NE\I[o5USU6JRWK=
A673 M4L4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIWwcVRKSzVyPUO0MlE4KG6P NXjJcJJXW0GQR1XS
VM-CUB-1 M4\Bemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HrOWlEPTB;M{SuOlkhdk1? M1\jfHNCVkeHUh?=
HH M3voT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrGSIRMUUN3ME2zOU4xPiCwTR?= MWfTRW5ITVJ?
CAL-27 NFjRZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nNUGlEPTB;M{WuNVYhdk1? NG[2cXZUSU6JRWK=
NEC8 NGjJR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTN3LkO3JI5O MkDsV2FPT0WU
BxPC-3 NYT4OJExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN4LkmxJI5O MkjTV2FPT0WU
SNB75 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnmS25tUUN3ME2zO{4zPCCwTR?= MlPXV2FPT0WU
NB13 NITSVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fydmlEPTB;M{iuNlMhdk1? MWnTRW5ITVJ?
SK-OV-3 NH3vVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TLRmlEPTB;M{iuO|Qhdk1? M4PNfHNCVkeHUh?=
ME-180 NG\rZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\DVJNJUUN3ME2zPE45KG6P NF\rNndUSU6JRWK=
JiyoyeP-2003 M1TjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rCcWlEPTB;M{muN|ghdk1? MV7TRW5ITVJ?
LU-134-A Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTRyLkCyJI5O NX;rOItFW0GQR1XS
LS-123 NYi5Now5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe1dotYUUN3ME20NE4zQCCwTR?= Mk\EV2FPT0WU
COLO-800 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLyTXVuUUN3ME20NE42PiCwTR?= MUHTRW5ITVJ?
LB831-BLC NUDSNoRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ntTWlEPTB;NEGuPFUhdk1? NWLwNXplW0GQR1XS
NCI-H747 NFfmZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfrfoRKSzVyPUSyMlI5KG6P NWSzUVFvW0GQR1XS
MZ7-mel M1zydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nUbWlEPTB;NEKuOlYhdk1? M1XuNXNCVkeHUh?=
GT3TKB NFHUcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nKUGlEPTB;NEKuO|Ihdk1? MV;TRW5ITVJ?
MOLT-16 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\BTWM2OD12Mz6wOUBvVQ>? M2HGfnNCVkeHUh?=
23132-87 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmxTWM2OD12Mz6wOUBvVQ>? MnTlV2FPT0WU
PF-382 M2rvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7sTWM2OD12ND6yNkBvVQ>? NX3F[FlFW0GQR1XS
ES3 NFq2XHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTR2Lk[gcm0> MnSwV2FPT0WU
SW756 NXT1OYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7kTWM2OD12NT6xOEBvVQ>? MoHOV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい
体内試験 Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

お薦めの試験操作（参考用のみ）

溶解度 (25°C)

体外 DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
体内 左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water (warmed)
混合させたのち直ちに使用することを推奨します。 		52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 263.2
化学式

C9H11F2N3O4
CAS No. 95058-81-4
保管 粉
in solvent
別名 LY-188011, NSC 613327

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

総分子量：g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03739619 Not yet recruiting Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Classical Hodgkin Lymphoma|Hodgkin Lymphoma Emory University|Bristol-Myers Squibb November 1 2019 Phase 1|Phase 2
NCT03541486 Not yet recruiting Pancreatic Neoplasm Joseph J. Cullen|Holden Comprehensive Cancer Center|University of Iowa April 1 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03669601 Not yet recruiting Cancer CCTU- Cancer Theme|AstraZeneca|Cambridge University Hospitals NHS Foundation Trust March 31 2019 Phase 1
NCT03690739 Not yet recruiting Recurrent Ovarian Carcinoma AGO Research GmbH February 1 2019 Phase 3
NCT03085004 Not yet recruiting Pancreatic Cyst|EUS-FNA Milton S. Hershey Medical Center January 2019 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問（FAQ）

  • 質問1：

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • 回答：

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

selleck catalog

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Tags: Gemcitabine を買う | Gemcitabine ic50 | Gemcitabine 供給者 | Gemcitabine を購入する | Gemcitabine 費用 | Gemcitabine 生産者 | オーダーGemcitabine | Gemcitabine 化学構造 | Gemcitabine 分子量 | Gemcitabine 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID